Thapsigargin, a promising broad-spectrum antiviral, has proven effective for use against SARS-CoV-2, as well as the influenza A and respiratory syncytial viruses (RSV), providing hope for a holistic approach to virus control. A team led by Kin-Chow Chang (University of Nottingham, UK), in collaboration with colleagues at China Agricultural University (Beijing, China), The Pirbright Institute and the Animal and Plant Health Agency (both UK), has uncovered the broad antiviral potential of a drug – thapsigargin – that could influence how future pandemics are managed. The study, published in Viruses, demonstrated the effectiveness of thapsigargin against three different respiratory illness-causing viruses. Given...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!